How can I screen for primary aldosteronism in a patient who cannot discontinue spironolactone while remaining on a beta‑blocker and an ACE‑inhibitor/ARB?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Screening for Primary Aldosteronism Without Withdrawing Spironolactone

You can proceed with screening for primary aldosteronism while the patient remains on spironolactone, beta-blockers, ACE inhibitors, and ARBs, but you must interpret the results with extreme caution and expect that spironolactone will likely render the screening uninterpretable. 1

The Core Problem with Spironolactone

Spironolactone is a mineralocorticoid receptor antagonist (MRA) that directly interferes with the aldosterone-renin axis by causing renin to escape suppression and reach very high levels 2. This fundamentally undermines the screening test, which relies on detecting suppressed renin with inappropriately elevated aldosterone. The 2025 Endocrine Society guidelines explicitly recommend a 4-week withdrawal period for MRAs when feasible 1.

Your Practical Approach: The "No-Withdrawal" Strategy

Since you cannot discontinue spironolactone, follow this algorithm:

Step 1: Proceed with Screening Despite Medications

  • Measure morning plasma aldosterone concentration (PAC) and plasma renin (activity or direct concentration) with the patient seated
  • Ensure potassium is corrected to normal range before testing (hypokalemia falsely lowers aldosterone) 1
  • Continue the beta-blocker, ACE inhibitor/ARB, and spironolactone

Step 2: Interpret Results with Medication-Specific Adjustments

For Beta-Blockers:

  • Beta-blockers suppress renin and can cause false-positive results 1
  • If aldosterone is >15 ng/dL (416 pmol/L) by immunoassay or >10 ng/dL (277 pmol/L) by LC-MS/MS, PA is likely despite the beta-blocker 1
  • If aldosterone is 10-15 ng/dL by immunoassay (or 7.5-10 ng/dL by LC-MS/MS), consider the result potentially false-positive from the beta-blocker 1

For ACE Inhibitors/ARBs:

  • These medications raise renin and can cause false-negative results 1
  • However, recent evidence suggests screening can be performed on these agents: if renin is undetectable despite ACE inhibitor/ARB use, PA is strongly suspected 1, 3
  • A 2026 study found that pre-washout ARR cutpoint of 2.69 (with RASIs on board) had 83.3% sensitivity and 87.2% specificity 3

For Spironolactone:

  • This is the most problematic medication—it causes renin to become very high and aldosterone may appear suppressed 2
  • The ARR will likely be falsely low, making PA screening essentially uninterpretable
  • If screening is negative on spironolactone, you cannot rule out PA—the test must be repeated after 4-week withdrawal when safe 1

Step 3: Decision Tree Based on Results

If screening is POSITIVE (elevated ARR with suppressed renin and elevated aldosterone):

  • Despite medications, this suggests PA
  • Proceed to confirmatory testing (saline infusion test or other aldosterone suppression test)
  • Consider repeating after withdrawing beta-blocker for 2 weeks if aldosterone is in the borderline range (10-15 ng/dL) 1

If screening is NEGATIVE or EQUIVOCAL:

  • This result is unreliable due to spironolactone 1
  • If pretest probability is moderate-to-high (resistant hypertension, hypokalemia), repeat testing after 4-week spironolactone withdrawal when medically safe 1
  • During the 4-week washout, substitute with non-interfering agents: alpha-1 blockers (doxazosin), hydralazine, or long-acting non-dihydropyridine calcium channel blockers (verapamil, diltiazem) 4

Critical Caveats

  1. Spironolactone makes negative results meaningless: You cannot exclude PA if the patient is on spironolactone and tests negative 1, 2

  2. Potassium correction is mandatory: Low potassium suppresses aldosterone secretion and causes false-negatives 1

  3. Context matters: Interpret results based on pretest probability. If the patient has resistant hypertension with hypokalemia, pursue diagnosis aggressively even with negative initial screening 1

  4. Local laboratory assays vary: ARR cutpoints differ between immunoassay and LC-MS/MS methods (approximately 25% lower with LC-MS/MS) 1

The Bottom Line

While you can technically screen on all these medications, spironolactone specifically will likely make your results uninterpretable if negative. The most pragmatic approach is to attempt a 4-week spironolactone washout using alternative non-interfering antihypertensives (alpha-blockers, hydralazine, or non-dihydropyridine calcium channel blockers), while continuing the beta-blocker and ACE inhibitor/ARB if blood pressure control requires it 1, 4. If washout is truly impossible due to safety concerns, proceed with screening but understand that a negative result cannot exclude PA and may require repeat testing under better conditions.

References

1
Guideline

primary aldosteronism: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2025

Related Questions

How should a patient with markedly elevated aldosterone, a high aldosterone-to-plasma renin activity ratio, elevated plasma normetanephrine and total metanephrine, normal ACTH, prior hypokalemia and hyponatremia, and who is taking lamotrigine, desvenlafaxine, and amlodipine be evaluated and managed?
How long should I discontinue losartan (angiotensin receptor blocker) before an aldosterone‑renin screening, and what alternative antihypertensive can I use during the washout period?
In a patient on amlodipine (Norvasc), metoprolol, losartan, spironolactone, and clonidine with aldosterone 9 ng/dL and renin 0.48 ng/mL/h, does he have primary hyperaldosteronism?
According to the latest guidelines, should angiotensin receptor blockers (ARBs), clonidine, amlodipine, and nebivolol be stopped before screening for primary aldosteronism?
What antihypertensive regimen should be used before measuring the aldosterone‑renin ratio in a patient being evaluated for hyperaldosteronism?
Can itopride cause drug‑induced parkinsonism?
What are the indications, recommended dosing, dose‑adjustment criteria, monitoring parameters, contraindications, and alternative therapies for pazopanib in patients with advanced renal cell carcinoma or metastatic soft‑tissue sarcoma?
Why is thyroid peroxidase antibody not elevated while anti‑thyroglobulin antibody remains positive in Hashimoto's thyroiditis?
Does eosinophilic esophagitis increase the risk of esophageal cancer?
What is the standard of care for anesthesia in spine surgery?
In a 67-year-old man with sleep‑onset and sleep‑maintenance insomnia who cannot tolerate zolpidem or eszopiclone and for whom benzodiazepines are undesirable, is suvorexant (Belsomra) appropriate, and what starting dose and safety precautions should be used?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.